Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil

Frontiers in Immunology

Immunology

Yuan Gao¹  Mengge Ding²  Yiguang Zhou²  Shun Jiang²  Chao Deng²  Dan Fan²  Xianling Liu²  Chaoyuan Liu²  Jiangbo He² 

[1] Department of Biomedical Education and Data Sciences, Temple University School of Medicine, Philadelphia, PA, United States;Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China;

关键词: Guillain–Barré syndrome;    immune checkpoint inhibitors;    immune-related adverse events;    KN046;    mycophenolate mofetil;   

DOI  :  10.3389/fimmu.2023.1132692

 received in 2022-12-27, accepted in 2023-04-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain–Barré syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously due to the self-limited nature of the disease, but severe cases can result in respiratory failure or even death. Here we report a rare case of GBS occurring in a 58-year-old male patient with non-small cell lung cancer (NSCLC) who developed muscle weakness and numbness of the extremities during chemotherapy combined with KN046, a PD-L1/CTLA-4 bispecific antibody. Despite receiving methylprednisolone and γ-globulin, the patient’s symptoms did not improve. However, there was significant improvement after treatment with mycophenolate mofetil (MM) capsules, which is not a routine regimen for GBS. To the best of our knowledge, this is the first reported case of ICIs-induced GBS that responded well to mycophenolate mofetil instead of methylprednisolone or γ-globulin. Thus, it provides a new treatment option for patients with ICIs-induced GBS.

【 授权许可】

Unknown   
Copyright © 2023 Ding, Deng, Liu, Jiang, Gao, Fan, Zhou, He and Liu